Sam Spigelman, MD

Head, Bladder Cancer, Oncology Global Medical Affairs at Janssen Oncology. Views expressed are my own, not those of J&J/Janssen. RTs are not endorsements.

[Sam Spigelman, MD @DocBladder]

@DeantheDream6 Contact me . Been a long time and CONGRATULATIONS on your success!!!!!

[Zach Klaassen @zklaassen_md]

#SUO24 @eugene_pietzak

The current state of BCG unresponsive NMIBC:
- Already FDA approved
- Likely will be FDA approved in the near future
- Off-label chemotherapy

@urotoday

[Sam Spigelman, MD @DocBladder]

@MAWildgust @JNJInnovMed @jonathanpentel @par_onc @MundleSuneel Marvelous to see old friends at Gustave Roussy . A big shout out to both Yohann Loriot and to our fantastic colleague Mattias 👍👍👍.

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Congratulations @jteoh_hk on this inspiring scientific meeting; a vivid reminder of the collective global pursuit of scientific advancement @CUHKMedicine @IBCG_BladderCA

[Sam Spigelman, MD @DocBladder]

@MAWildgust @jillfeldman4 @JNJInnovMed I am also humbled

[Sam Spigelman, MD @DocBladder]

@MAWildgust Another win for prostate cancer patients !

[Mark Wildgust (he/him) @MAWildgust]

Delighted to announce US FDA approval of AKEEGA (Dual Action Tablet of Niraparib and Zytiga) for patients with mCRPC prostate cancer with BRCA alterations.

https://t.co/PfHKuFxI2r

[Uromigos @Uromigos]

Great results for Erdafitinib in FGFR +ve non muscle invasive bladder cancer with Siamak Daneshmand . Great Data #GU23

[Sam Spigelman, MD @DocBladder]

@UroDocAsh @NEJM @AtlanticUrology just the best from the one of the best

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Congratulations Neal!

https://t.co/bkZ2XafPSv @NEJM @AtlanticUrology

[Ignacio Rguez. Gomez @urogomez_]

OOOpppsss....
@Uroweb @EAU_Uroonco @InfoAeu @GUOaeu @MariaJRibal
FDA Does Not Approve Vicinium for BCG-unresponsive NMIBC https://t.co/IoGup1FV3p a través de @targetedonc

[Johnson & Johnson Innovation @JNJInnovation]

Timely diagnosis is critical for rare diseases like #ALamyloidosis.

Announcing the Improving Detection of AL Amyloidosis (IDEA) #QuickFireChallenge: submit ideas for optimizing detection & early diagnosis of this rare disorder https://t.co/DVWo3rQUJ3 #AmyloidosisAwarenessMonth

[UroToday.com @urotoday]

SUB-urothelial DUrvalumab injEction-1 (SUBDUE-1) - A #ClinicalTrial for the novel administration of immunotherapy for #BladderCancer. Dickon Hayne @uwanews joins @UroDocAsh @MDAndersonNews to discuss the results on UroToday > https://t.co/QoeO9f32mq @ANZUPtrials

[Andrea Necchi, MD, FASCO @AndreaNecchi]

I am pleased to share our last platinum priority paper from collaborative work: Molecular Characterization of Residual Bladder Cancer after Neoadj Pembrolizumab @ewanagibb @JoepJdeJong @pcvblack @Roland3097 @DanieleRaggi83 @LauraLmar89 #PURE01 @EUplatinum https://t.co/9YScPezEoj

[Sam Spigelman, MD @DocBladder]

Fantastic research!!. Thank you Dr. N

[Vivek Subbiah, MD @VivekSubbiah]

1/5 Tweetorial
🚨⭐️What a great precision medicine story !

🚨First came the NTRK fusion story 👉 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children @NEJM @DavidHongMD @DHymanMD @alexdrilon @OncoAlert @FAndreMD https://t.co/5WiDDZ5uG4

[Sam Spigelman, MD @DocBladder]

@UroDocAsh @ASCO Agree with Ashish!!

[Sam Spigelman, MD @DocBladder]

@garysteinbergmd @saumyg @RutgersCancer @USC_Urology @SanamLadi @syan_sumeet @siadaneshmand @BCAN_NCT @RyanWerntzMD Absolutely agree with Gary

[Friends of Cancer Research @CancerResrch]

JUST RELEASED: We've published w/ @ASCO our latest recommendations to expand patient access to cancer clinical trials by further broadening eligibility criteria. For more information: https://t.co/zQzODxUY2v #WhatFriendsDoes #clinicaltrials #FDA @CCR_AACR

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️The new version V3.0 is out ➡️ The Swiss Cheese Respiratory Pandemic Defense Against #COVID19 model from @MackayIM 👏🏼 includes #vaccines
👉🏼Personal +shared responsibilities✅
👉🏼Multiple layers improve success✅
#InThisTogether #EndCovid